A case of colon cancer recurrence in the uterus

Dorcas C Morgan, Natalie Berger, Konstantin Zakashansky

ABSTRACT

Introduction: Findings of colon cancer metastases in the uterus are rare. In this case report, an isolated recurrence of colon cancer in the uterus that originated in the transverse colon has been described. It was initially thought to be a uterine leiomyoma on positron emission tomography–computed tomography (PET–CT) scan.

Case Report: A 66-year-old woman with a known history of colon carcinoma presented with increasing carcinoembryonic antigen (CEA) levels six months after resection of primary adenocarcinoma of the transverse colon. Two inconclusive PET/CT scans were performed over two years in an effort to identify disease. Carcinoembryonic antigen continued to rise. Two years after the initial rise in CEA, a hypermetabolic area in the uterus, initially thought to be a uterine leiomyoma, was deemed suspicious on PET/CT scan. Total laparoscopic hysterectomy and bilateral salpingo-oophorectomy confirmed the diagnosis of metastatic adenocarcinoma of colonic origin in the uterine serosa, myometrium and endometrium.

Conclusion: Approximately, 200 cases of extragenital primaries with metastasis to the female genital tract have been described. Of those, breast is the most commonly seen followed by colon cancer. While colon cancer is known to metastasize to the ovaries, metastatic spread to the uterus is possible as well [1]. Therefore, all postmenopausal women undergoing surgery for colorectal cancer should be counseled regarding possible metastatic disease in the ovaries and/or uterus and should consider removal of these organs at the time of the initial surgery for staging of disease.

International Journal of Case Reports and Images (IJCRI)

International Journal of Case Reports and Images (IJCRI) is an international, peer reviewed, monthly, open access, online journal, publishing high-quality, articles in all areas of basic medical sciences and clinical specialties.

Aim of IJCRI is to encourage the publication of new information by providing a platform for reporting of unique, unusual and rare cases which enhance understanding of disease process, its diagnosis, management and clinico-pathologic correlations.

IJCRI publishes Review Articles, Case Series, Case Reports, Case in Images, Clinical Images and Letters to Editor.

Website: www.ijcasereportsandimages.com

(This page in not part of the published article.)
A case of colon cancer recurrence in the uterus

Dorcas C Morgan, Natalie Berger, Konstantin Zakashansky

ABSTRACT

Introduction: Findings of colon cancer metastases in the uterus are rare. In this case report, an isolated recurrence of colon cancer in the uterus that originated in the transverse colon has been described. It was initially thought to be a uterine leiomyoma on positron emission tomography–computed tomography (PET–CT) scan. Case Report: A 66-year-old woman with a known history of colon carcinoma presented with increasing carcinoembryonic antigen (CEA) levels six months after resection of primary adenocarcinoma of the transverse colon. Two inconclusive PET/CT scans were performed over two years in an effort to identify disease. Carcinoembryonic antigen continued to rise. Two years after the initial rise in CEA, a hypermetabolic area in the uterus, initially thought to be a uterine leiomyoma, was deemed suspicious on PET/CT scan. Total laparoscopic hysterectomy and bilateral salpingo-oophorectomy confirmed the diagnosis of metastatic adenocarcinoma of colonic origin in the uterine serosa, myometrium and endometrium. Conclusion: Approximately, 200 cases of extragenital primaries with metastasis to the female genital tract have been described. Of those, breast is the most commonly seen followed by colon cancer. While colon cancer is known to metastasize to the ovaries, metastatic spread to the uterus is possible as well [1]. Therefore, all postmenopausal women undergoing surgery for colorectal cancer should be counseled regarding possible metastatic disease in the ovaries and/or uterus and should consider removal of these organs at the time of the initial surgery for staging of disease.

Keywords: Colon cancer, Postmenopausal women, Uterus, Uterine leiomyoma

INTRODUCTION

Colon cancer is the third most common cancer and the third leading cause of cancer death in women. It is treated surgically. Prophylactic oophorectomy is a consideration when women are undergoing surgery for the treatment of colon cancer and are through with childbearing. This addresses concerns of possible metastasis of colon cancer to the ovary. It is believed that the ovaries appear to be a fertile bed for metastases and a sanctuary site for chemotherapy. Our report indicates that the uterine body may harbor metastases as well without ovarian involvement. The presence of uterine leiomyoma may present additional difficulty in making timely diagnosis of recurrence. Uterine leiomyoma is the most common tumor of female reproductive tract. They may have hypermetabolic activity on positron emission...
tomography–computed tomography (PET-CT) scan. This activity may vary with reproductive age. Metastatic disease from the colon to the uterus is rare [1]. Therefore, the removal of the uterus, a hysterectomy, is usually not considered when a woman is undergoing surgery for colon cancer. We present a case of recurrent colon cancer in the uterus initially thought to be a uterine leiomyoma on PET-CT scan.

CASE REPORT

A 66-year-old female G2P2002 was diagnosed with colon cancer on routine colonoscopy. She underwent colonic resection for adenocarcinoma of the transverse colon (pT4apN0Mx). Surgical pathology showed a moderately differentiated adenocarcinoma, grossly measuring 4.0x3.5 cm, infiltrating through the serosa onto a small portion of adherent omentum. No lymphovascular invasion was seen. Seventeen regional lymph nodes were negative for cancer cells. Resected margins were free of disease. Surgery was followed by adjuvant chemotherapy with xeloda for six months, which the patient tolerated well.

The patient was doing well, however, six months after surgery her carcinoembryonic antigen (CEA) rose from 2.2–3.4 ng/mL. The patient was monitored closely. Eight months after the surgery, CEA continued to be elevated, 3.5 ng/mL, although her examination was unremarkable. A PET-CT scan was performed and showed no evidence of metastatic disease. Ten months after her initial surgery the CEA continued to rise and was 10.7 ng/mL. Another PET-CT scan was performed. Results revealed an area of focal hypermetabolism along the left lateral uterine fundus versus the left adnexa, maximum SUV 8.3. Further evaluation with pelvic magnetic resonance imaging (MRI) scan suggested a left intramural fundal uterine leiomyoma with submucosal extension measuring 2.2x2.2x2.3 cm. This corresponded to the area of concern on the prior PET-CT scan.

Tumor markers continued to be followed and CEA levels continued to rise. A PET-CT scan was repeated 32 months after the original surgery, and reported that the hypermetabolism was again present along the left lateral uterine fundus; however it was unusually high for a myoma with an SUV of 8.8. Another pelvic ultrasound was recommended. The CEA level at that time was 27.1 ng/mL. CEA levels rose to 46.1 ng/mL and another PET/CT scan, 3 years and 1 month after the original surgery was performed. It again demonstrated increased increase in metabolic activity in the left uterine fundus. Another hypermetabolic area was seen posterior to the uterus, (Figure 1) which likely represented a lymph node. The patient was referred to gynecologic oncology. She underwent a laparoscopic total hysterectomy and bilateral salpingo-oophorectomy. The left lower uterine segment was described as having an exophytic lesion suggestive of cancer grossly extending into the uterine myometrium. The lesion measured 2.8 cm x 2.6 cm. The tumor was located in the lower anterior uterine wall, involving the serosal margin. It penetrated the uterine serosa, went through the myometrium and involved the endometrium. No lymphovascular invasion was seen. The cervix, both ovaries and fallopian tubes were free of carcinoma. Immunohistochemical stains revealed tumor cells positive for AE1/3, CK20, CDX2, and TTF1 (focal and weak) and negative for CK7, GCDFP-15, HepPar1, Napsin A, PAX8, synaptophycin, vimentin, ER and PR. The Ki-67 labeling index was about 40%. These results were consistent with the patient’s known colon carcinoma.

DISCUSSION

Colorectal cancer is the third most common cancer affecting women and the third most common cause of cancer death in women. Colon cancer is known to metastasize to the lymph nodes, lungs, liver, and peritoneum. Within the female genital tract it is known to metastasize to the ovaries, however, uterine metastases
are rare [1]. Colon cancer is usually treated surgically and depending on the stage, adjuvant chemotherapy may be offered. Close follow-up within the first two years of resection is imperative to identify recurrences within a timely manner. In 1964 Gold and Freedman [2] reported their identification a tumor specific antigen for human colonic carcinoma, CEA. Since then it has been widely used to monitor response to treatment interventions as well as recurrence of disease. Increasing CEA require additional test be performed to detect recurrences, these include computed tomography (CT) scan or magnetic resonance imaging (MRI) scan of the abdomen and chest, MRI and possible positron emission tomography (PET) scan.

The PET-CT scans with FDG (18F-fluorodeoxyglucose) are commonly used at the initial disease staging as well as monitoring for recurrent disease. The FDG usually gives off higher signal (SUV) in the areas where malignant cells are present. However, benign tissues with high cell turnover rate are known to have higher FDG uptake rates. In the case of this patient, it was believed that her uterine leiomyoma was the likely source of the increased uptake. The literature varies in its reporting of FDG activity in leiomyomas. Recent studies suggest FDG uptake in uterine leiomyomas may be influenced by estrogen. Kitajima et al. [3] reported mean values of the maximum and average SUVs for a total of 61 leiomyomas were 2.34 +/- 0.75 and 1.74 +/- 0.5, respectively. They reported a negative correlation between maximum and average SUVs and age. In a postmenopausal woman, therefore, the FDG uptake should be low. In this patient it was much higher than reported for any age woman with leiomyomas. Nishizava et al. [4] also reported FDG uptake in uterine leiomyomas in pre- and postmenopausal women. The uptake was reported in 10.4 % of premenopausal women and only 1.4% of postmenopausal women. The uptake was reported to vary with the menstrual cycle and usually disappeared with menopause. SUV’s varied from 3.5 to 16. Lerman et al. [5] conducted a retrospective study investigating the FDG uptake in uterine leiomyomas in women with non-gynecologic malignancies who underwent PET-CT scans. They were able to categorize women based on menstrual cycle and menopause status as well as women with known exposure to selective estrogen receptor modulators (SERMs). They found that the mean FDG uptake was significantly higher in premenopausal women when compared to postmenopausal, 1.47 +/- 0.32 SUV compared to 1.29 +/- 0.41 SUV. Women with a history of breast cancer and SERM were found to have significantly lower FDG uptake in their uterine leiomyomas compared to untreated women. The SUV’s reported in our patient varied from 8.3 to 8.8 were therefore higher than reported in any of the studies in postmenopausal women.

Women diagnosed with colorectal cancer have been found to have metastatic disease to the ovaries 3–14% [6]. The exact mechanism is not clear. Many mechanisms have been proposed including hematogenous and lymphatic spread to direct extension [7]. Because of this concern, there has been support, albeit controversial that women who undergo surgical intervention for treatment of colorectal cancer be counseled to have removal of both ovaries at the time of the initial surgery even if there no evidence of disease on imaging studies [8]. In our case, we present a rare finding of colorectal cancer metastasizing to the uterus. Extragential primary cancers metastasizing to the uterus was reported in a small case series [1]. There were 11 cases identified at autopsy or surgery. They had documented metastasis from colon to uterus and were more likely to involve the myometrium and spare the endometrium. Our patient had involvement of serosa, myometrium and endometrium. And while there was microscopic and gross evidence of metastasis in our patient, she did not have a history of postmenopausal bleeding and therefore did not have a clinical indication for evaluating her endometrium. At the time of the hysterectomy, her ovaries appeared free of disease and were not found to have histological evidence of metastasis.

CONCLUSION

Our case demonstrates a rare finding of a isolated colorectal cancer metastasis to the uterus in a patient with a known history of uterine leiomyomas. Caution is required in interpreting PET-CT scan results in patients with uterine fibroids. A consideration should be given to performing prophylactic hysterectomy at the time of prophylactic oophorectomy in patients with advanced colon cancer.

*********

Acknowledgements
Alexander Vidershayn, M.D. for PET-CT scan image.

Author Contributions
Dorcas C Morgan – Substantial contributions to conception and design, Acquisition of data, Analysis and interpretation of data, Drafting the article, Revising it critically for important intellectual content, Final approval of the version to be published
Natalie Berger – Acquisition of data, Analysis and interpretation of data, Drafting the article, Final approval of the version to be published
Konstantin Zakashansky – Substantial contributions to conception and design, Revising it critically for important intellectual content, Final approval of the version to be published

Guarantor
The corresponding author is the guarantor of submission.

Conflict of Interest
Authors declare no conflict of interest.
REFERENCES


Access full text article on other devices

Access PDF of article on other devices
About Edorium Journals
Edorium Journals is a publisher of high-quality, open access, international scholarly journals covering subjects in basic sciences and clinical specialties and subspecialties.

Invitation for article submission
We sincerely invite you to submit your valuable research for publication to Edorium Journals.

But why should you publish with Edorium Journals?
In less than 10 words - we give you what no one does.

Vision of being the best
We have the vision of making our journals the best and the most authoritative journals in their respective specialties. We are working towards this goal every day of every week of every month of every year.

Exceptional services
We care for you, your work and your time. Our efficient, personalized and courteous services are a testimony to this.

Editorial Review
All manuscripts submitted to Edorium Journals undergo pre-processing review, first editorial review, peer review, second editorial review and finally third editorial review.

Peer Review
All manuscripts submitted to Edorium Journals undergo anonymous, double-blind, external peer review.

Early View version
Early View version of your manuscript will be published in the journal within 72 hours of final acceptance.

Manuscript status
From submission to publication of your article you will get regular updates (minimum six times) about status of your manuscripts directly in your email.

Our Commitment

Six weeks
You will get first decision on your manuscript within six weeks (42 days) of submission. If we fail to honor this by even one day, we will publish your manuscript free of charge.

Four weeks
After we receive page proofs, your manuscript will be published in the journal within four weeks (31 days). If we fail to honor this by even one day, we will publish your manuscript free of charge and refund you the full article publication charges you paid for your manuscript.

Mentored Review Articles (MRA)
Our academic program “Mentored Review Article” (MRA) gives you a unique opportunity to publish papers under mentorship of international faculty. These articles are published free of charges.

Most Favored Author program
Join this program and publish any number of articles free of charge for one to five years.

Favored Author program
One email is all it takes to become our favored author. You will not only get fee waivers but also get information and insights about scholarly publishing.

Institutional Membership program
Join our Institutional Memberships program and help scholars from your institute make their research accessible to all and save thousands of dollars in fees make their research accessible to all.

Our presence
We have some of the best designed publication formats. Our websites are very user friendly and enable you to do your work very easily with no hassle.

Something more...
We request you to have a look at our website to know more about us and our services.

We welcome you to interact with us, share with us, join us and of course publish with us.

CONNECT WITH US

Edorium Journals: On Web
Browse Journals